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Abstract 9 
Antimicrobial resistance frequently carries a fitness cost to a pathogen, measured as 10 
a reduction in growth rate compared to the sensitive wild type, in the absence of 11 
antibiotics. Existing empirical evidence points to the following relationship between 12 
cost of resistance and virulence. If a resistant pathogen suffers a fitness cost in terms 13 
of reduced growth rate it commonly has lower virulence compared to the sensitive 14 
wild type. If this cost is absent so is the reduction in virulence. Here we show, using 15 
experimental evolution of drug resistance in the fungal human pathogen Candida 16 
glabrata, that reduced growth rate of resistant strains need not result in reduced 17 
virulence. Phenotypically heterogeneous populations were evolved in parallel 18 
containing highly-resistant sub-population small colony variants alongside sensitive 19 
sub-populations. Despite their low growth rate in the absence of an antifungal drug, 20 
the small colony variants did not suffer a marked alteration in virulence compared 21 
with the wild-type ancestral strain, or their co-isolated sensitive strains. This contrasts 22 
with classical theory that assumes growth rate to positively correlate with virulence. 23 
Our work thus highlights the complexity of the relationship between resistance, basic 24 
life-history traits and virulence. 25 
 26 
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Introduction 32 
 33 
The rise of antimicrobial resistance (AMR) presents a major challenge to modern 34 
healthcare [1] but it is ultimately an ecological problem [2]. In natural environments, 35 
be it within or outside a host, susceptible and resistant microorganisms compete with 36 
each other [3]. While the use of antimicrobials promotes the growth of resistant 37 
strains or species [4], resistance frequently carries a fitness cost that arises when the 38 
antimicrobial is withdrawn [5-8]. The question we address here is this: how do 39 
virulence and resistance traits interact, costs of resistance in particular? 40 
 41 
For a pathogenic microorganism, resistance costs are commonly measured as 42 
reductions in growth rate [5, 7, 9] which are often associated with reductions in 43 
virulence [8, 10, 11]. For example, resistant small colony variants isolated from 44 
otherwise susceptible populations [12] have lower growth rate than the suscpetible 45 
isolates they were found amongst in the absence of antibiotics but are also less 46 
virulent [13]. By contrast, resistant strains that do not suffer reduction in growth rates, 47 
either through “no-cost” or compensatory mutations, have been found not to have 48 
impaired virulence [8, 10, 14, 15]. Therefore, the existing empirical evidence 49 
suggests that the existence of virulent resistant or multi-resistant infections (as 50 
observed in [8]) is only possible when resistance costs are absent.  51 
 52 
Here we challenge this reasoning by providing a counter example. While theory [16, 53 
17] and within-species empirical studies [18, 19] argue that growth rate positively 54 
correlates with virulence, a between-species meta-analysis suggests that growth rate 55 
and virulence might not be positively correlated [20]. Thus, we hypothesise that 56 
virulence could be maintained following the evolution of costly resistance if a 57 
reduction in within-species growth rate does not lead to a reduction in virulence. 58 
 59 
We deployed an experimental system using the human fungal pathogen Candida 60 
glabrata, ideally placed to test this hypothesis. In particular, the opportunistic 61 
pathogen C. glabrata undergoes rapid acquisition of resistance to the main classes of 62 
clinical antifungals [21, 22] and resistance can impart a growth fitness cost [11]. 63 
Crucially for testing our hypothesis, we recently observed attenuated virulence in a 64 
fast-growing C. glabrata strain [23, 24] which would suggest the potential lack of a 65 
positive relationship between growth rate and virulence. 66 
 67 
C. glabrata is a pathogen of clear clinical importance as it is the second most 68 
commonly isolated Candida species in bloodstream infections [25] with a greater than 69 
50% death rate [26]. It is more closely related to the well-established model yeast 70 
Saccharomyces cerevisiae than to other species of the Candida genus [27]. As such, 71 
molecular, genetic and evolutionary techniques can readily be transferred from S. 72 
cerevisiae to C. glabrata making it an increasingly popular model organism to study 73 
infection [28-31]. 74 
 75 
After 14 seasons of transfer in post-MIC echinocandin (caspofungin) treatment, we 76 
found independent evolution of two C. glabrata heterogeneous populations consisting 77 
of diverse co-isolated colony morphologies with divergent resistance and growth 78 
properties. In both populations, a small colony variant phenotype was associated with 79 
a low growth rate and high resistance level. Interestingly, the small colony phenotype 80 
retained virulence in a wax moth larval infection model, comparable to the wild-type 81 
ancestor and co-isolated population colonies experiencing faster growth. These 82 
results suggest that virulence could be maintained in the presence of costly 83 
resistance that results in a reduced growth rate. In addition, we found no evidence of 84 
a correlation between in vitro growth rate and virulence across sub-population colony 85 
variants. Our work therefore questions the current understanding of the relationship 86 
between growth rate and virulence. 87 
 88 
Methods 89 
In vitro evolution of C. glabrata populations on a gradient of caspofungin 90 
concentrations  91 
The reference C. glabrata strain ATCC 2001 [32] was used as the wild-type ancestor 92 
of all evolving replicate populations and was denoted as ‘2001WT’. Triplicate 93 
populations were evolved across a gradient of eight caspofungin concentrations of 94 
clinical relevance [33] and drug-free condition in a 96-well microtiter plate 95 
(Supplementary Figure 1a) in 10 mg ml-1 glucose Synthetic Complete (SC) medium 96 
(0.67% w/v yeast nitrogen base without amino acids and 0.079% w/v synthetic 97 
complete supplement mixture (Formedium)). Caspofungin concentrations in SC were 98 
prepared from stock solution (5 mg ml-1). Populations were serially transferred (1:30 99 
dilution) every 24 hours to fresh media and drug conditions for 14 days. The 96-well 100 
plate was incubated at 30oC over 24 hours with shaking. OD (Optical Density) was 101 
read at 650 nm wavelength in a microtiter plate reader. The whole experiment was 102 
repeated on three separate 14-day periods (Experiments A, B and C).  103 
 104 
OD data was blank-corrected and percentage relative growth at 24 hours, for each 105 
drug-treated population, was presented relative to the mean OD of the no drug-106 
treated populations [34] (Supplementary Figure 2). We used the lme4 package [35] 107 
with R version 3.4.3 [36] to conduct a linear mixed effects analysis of the fixed effects 108 
of day of the evolutionary experiment and caspofungin concentration on relative 109 
growth of C. glabrata. ‘Population’ was included as a nested random effect within 110 
‘Experiment’ as each population was repeatedly measured across days of the 111 
evolutionary experiment. We obtained p-values from likelihood ratio tests. 112 
 113 
Growth profiling of caspofungin-evolved endpoint colonies 114 
All nine C. glabrata populations (Experiments A-C) that were evolved at 0.78, 1.37 115 
and 2.40 µg/ml of caspofungin were revived from day 14 (Supplementary Figure 1b). 116 
We identified two distinct colony size variants hereby named SCV (Small Colony 117 
Variant) and RCV (Regular Colony Variant) in a single population from each of 118 
Experiment A and B but not C, and only at 0.78 µg/ml, shown in Supplementary 119 
Figure 3. Colony variants from Experiment A were growth-profiled in SC 1% w/v 120 
glucose media across replicate wells of a 96-well plate (N=4 wells x 3 separate day 121 
repeats = 12). OD was measured over 24 hours. Data from Experiment A are plotted 122 
in Figure 1a and b. Growth was measured in 4 replicate wells (N=4) of a 96-well plate 123 
for each of the SCV and RCV from Experiment B with data plotted in Supplementary 124 
Figure 4a and b.  125 
 126 
Data was imported into MATLAB [37] to approximate intrinsic growth rate via logistic 127 
growth model fitting as described in [24], with exclusion of the lag phase parameter L. 128 
Relative growth rate and final growth yield were obtained by dividing through by the 129 
mean values of the 2001WT strain. We fitted a linear mixed effects model to relative 130 
growth rate and yield data from Experiment A and Experiment B using the lme4 131 
package [35] with R version 3.4.3 [36]. We included colony variant type as a fixed 132 
factor and day of measurement as a random factor. A likelihood ratio test was used 133 
to test significance of the fixed factor.  134 
 135 
Dose response profiling 136 
We measured the caspofungin dose response profile over 24 hours for the co-137 
isolated small and regular-sized colony variants from Experiments A and B and the 138 
wild-type ancestral strain (2001WT), to calculate IC50 (drug concentration causing 139 
50% growth inhibition). Dose responses were set up in 96-well microtiter plates, 140 
using the same methods as described in the first season of the in vitro evolution 141 
assay (Supplementary Figure 1a). For colony variants that were resistant to 142 
concentrations up to 2.40 µg/ml, a two-fold dilution series from 64 µg/ml was used. 143 
Microtiter plates were incubated at 30oC over 24 hours with orbital shaking and OD 144 
measurement.  Dose responses were repeated three times independently for 145 
Experiment A (N = 3 wells x 3 repeats = 9 per caspofungin concentration) shown in 146 
Figure 1c and d. Dose responses were run once for Experiment B (N = 3 per 147 
caspofungin concentration) shown in Supplementary Figure 4c and d. The best-fit 4-148 
parameter logistic dose response was plotted using R-package ‘drc’ [38], as 149 
described in [34] and used to estimate IC50. 150 
 151 
Small colony phenotypes  152 
Serial passaging 153 
We tested stability of the randomly-selected SCV isolated from the single evolved 154 
population exhibiting colony diversity from each of Experiments A and B. A single 155 
overnight culture of each SCV was adjusted to 6.49 x 105 cells/ml, diluted 2-fold and 156 
serially passaged (1:30 dilution) across triplicate populations in 10 mg ml-1 glucose 157 
SC medium over 14 days. (Supplementary Figure 1d). The plate was incubated at 158 
30°C with shaking at 180rpm and OD was measured during each 24-hour season. 159 
Growth rate and yield data from the final growth cycle are plotted in Figure 2 160 
alongside 2001WT, with two-sample t-tests used to detect growth differences 161 
between 2001WT and passaged populations of each SCV. Caspofungin dose 162 
response was measured for a single clone cultured from each preserved endpoint 163 
(day 14) population (Supplementary Figure 1d), across triplicate wells for each 164 
caspofungin concentration. Endpoint passage population colony morphologies and 165 
dose response are presented in Supplementary Figure 5 for a single population 166 
(representative of three) of the passaged SCV from each of Experiment A and B. 167 
 168 
Characterisation of genomic targets 169 
Genomic DNA was extracted from 2001WT and the single isolated SCV and RCV 170 
variants from each of Experiments A and B by mechanical cell lysis as described in 171 
[39]. Briefly, cells were grown overnight, centrifuged and mixed with Smash and Grab 172 
Solution (1% SDS, 2% Triton-X, 100 mM NaCl, 10 mM Tris pH 8.0), phenol-173 
chloroform and acid-washed glass beads. The HS1 and HS2 regions of the FKS1 174 
and FKS2 genes were amplified by PCR and Sanger-sequenced using primers 175 
previously described [40, 41]. Amplification of genes CDC6, DOT6, MRPL11, SUI2 176 
was performed using primers described for C. glabrata [11].  177 
 178 
Competitive fitness assay between SCV and RCV (Experiment A) 179 
To test competitive fitness of the stable SCV isolated from Experiment A against its 180 
co-isolated RCV, the two colony variants were competed across a set of mixed strain 181 
ratios in SC 1% glucose medium supplemented with 0.78 µg/ml caspofungin in wells 182 
of a 96-well plate (Supplementary Figure 6). Each strain was adjusted to 6.49 x 106 183 
cells/ml prior to mixing and subsequent 2-fold dilution in SC media. Each mixed strain 184 
ratio was added to triplicate wells. The plate was incubated at 30°C with shaking at 185 
180rpm. Competition mixes were plated on SC 1% glucose agar plates at the start 186 
(N=3) and end (N= 3 wells x 3 plates =9) of 24-hour growth, on which the colony 187 
morphotypes could clearly be distinguished by size. Relative fitness of the SCV was 188 
calculated as the ratio of the Malthusian growth parameters of the SCV and RCV 189 
[42]. A least-squares linear regression of relative fitness against initial SCV frequency 190 
was plotted and statistically analysed in Excel [43]. Two-tailed one-sample t-tests in 191 
R version 3.4.3 [36] tested significant deviations of relative fitness values from one.  192 
 193 
Galleria mellonella survival assays 194 
The 2001WT strain, regular colony, unpassaged and passaged small colony variants 195 
were tested for virulence in G. mellonella wax moth larvae. C. glabrata strains were 196 
grown in SC (2% glucose) media for 24 hours at 30ºC, cells were washed twice in 197 
PBS, counted on a haemocytometer and adjusted to 2.5 x 108 cells/ml in PBS with 20 198 
µg/ml ampicillin.  Groups of 20 wax moth larvae (UK Waxworms Ltd, Sheffield), 199 
selected based on their weight (0.25-0.35g) and lack of visible melanisation, were 200 
injected with 10 µl spore suspension (2.5 x 106 CFU / larva) using a 50 µl Hamilton 201 
syringe into their last left pro-leg.  Larvae were maintained at 37 ºC in the dark and 202 
monitored for survival. Three independent replicates of survival assays were 203 
performed on separate days (N=20 x 3 = 60 larvae in total per C. glabrata strain). A 204 
control group of 10 larvae injected with PBS and ampicillin were run alongside each 205 
independent replicate, and no deaths were seen. Mean survival time and log-rank 206 
comparisons of survival curves were calculated using OASIS 2 [44] for each of the 207 
three replicates. As routinely done with G. mellonella survival assays [45, 46], data 208 
from one of the replicates is presented in the main manuscript (Figure 3) while the 209 
data from the other two are presented in Supplementary Material (Supplementary 210 
Figures 7 and 8). 211 
 212 
Testing for correlations between larval survival time and growth rate or yield 213 
The mean relative growth rates or yields for each of the strains from Experiments A 214 
and B (reported in Figures 1a and b, 2, and Supplementary Figure 4a and b) were 215 
plotted against their virulence calculated as larval survival time from either Figure 3 216 
(first replicate survival study), Supplementary Figure 7 (second replicate survival 217 
study) or Supplementary Figure 8 (third replicate survival study); this generated 218 
Figure 4, Supplementary Figure 10a and Supplementary Figure 11a, respectively. 219 
Note, as growth trait replicate measurements were not directly paired with larval 220 
survival time measurements, their mean values were plotted with standard error bars 221 
representing the variability in estimation. Bootstrapping was performed on data in 222 
Figure 4, Supplementary Figure 10a and Supplementary Figure 11a both for Linear 223 
and Deming regressions and also for Pearson and Spearman correlations (using 224 
MATLAB's Statistics and Machine Learning Toolbox) [37]. The resulting statistics are 225 
reported in  Supplementary Figures 9a and b and Supplementary Figures 10-11b and 226 
c.  227 
 228 
Results 229 
 230 
Rapid evolution of sub-population phenotypic diversity with antifungal 231 
caspofungin treatment  232 
We measured growth adaptations of populations of the reference C. glabrata strain 233 
ATCC 2001 (denoted 2001WT), serially transferred over 14 days and evolving across 234 
a gradient of 8 antifungal caspofungin concentrations (see Methods). Growth across 235 
C. glabrata populations, relative to no-drug treated controls, significantly increased 236 
over time (effect of day: likelihood ratio test: χ2(2) = 52.297, p =4.404e-12 ) 237 
(Supplementary Figure 2). Growth was also significantly influenced by caspofungin 238 
concentration (likelihood ratio test: χ2 (1) = 154.6, p < 2.2e-16). The greatest relative 239 
population growth increase from 3.0 +/- 2.5 (SE) % on day 1, to 88.8 +/- 7.0 (SE) % 240 
on day 14 occurred at 0.78 µg/ml of caspofungin.  241 
 242 
We revived triplicate endpoint (day 14) populations that were evolved at the three 243 
highest caspofungin concentrations (0.78, 1.37 and 2.40 µg/ml), to phenotype colony 244 
morphologies (Supplementary Figure 1b). We identified colony size variation in a 245 
single population from Experiment A and a single population from Experiment B, 246 
which had both been evolved during treatment in 0.78 µg/ml caspofungin. Two size 247 
variants were observed in each of these populations: a small colony variant (SCV) 248 
and a regular colony variant (RCV) (Supplementary Figure 3).  We did not observe 249 
the SCV phenotype in any populations from Experiment C. The small colony 250 
morphology and lower growth rate of the isolated SCV resembled the respiratory-251 
deficient petite phenotype previously observed for C. glabrata [11], however our SCV 252 
strains were able to grow on a non-fermentable carbon source, indicating respiratory 253 
function (Supplementary Figure 3). 254 
 255 
We measured growth rates and final population densities (yield) of the SCV and RCV 256 
strains, relative to strain 2001WT in the absence of caspofungin. Relative growth rate 257 
significantly varied with colony type (Experiment A (Figure 1a):  χ2(2) = 73.376, p < 258 
2.2e-16; Experiment B (Supplementary Figure 4a): χ2(2) = 69.543, p = 7.926e-16). 259 
No significant differences were found between 2001WT and RCV, but growth rate of 260 
SCV was significantly lower than both 2001WT and RCV.  261 
 262 
Relative growth yield significantly varied with colony type (Experiment A (Figure 1b): 263 
χ2(2) = 21.454, p = 2.195e-05; Experiment B (Supplementary Figure 4b): χ2(2) = 264 
34.644, p = 3e-08). Growth yield of the SCV was significantly greater than both 265 
2001WT and the RCV. In Experiment B only, yield of the RCV was significantly lower 266 
than 2001WT.   267 
 268 
We next measured the caspofungin dose response of the variants from Experiments 269 
A and B that were growth profiled. Caspofungin susceptibility profiles of the two 270 
colony variants were highly divergent. From Experiment A, the RCV (Reg_Col) had 271 
an IC50 of 0.26 +/- 0.007 µg/ml that was slightly lower (marginally significantly) than 272 
the 2001WT strain IC50 (0.32 +/- 0.0025 µg/ml; p = 0.0454) (Figure 1c). The co-273 
isolated SCV (Small_Col) however was not susceptible to caspofungin 274 
concentrations up to 2.4 µg/ml (Figure 1d) and had an IC50 of 2.61 +/- 0.136 µg/ml, 275 
approximately 10-fold greater than the IC50 of the co-isolated regular colony variant 276 
and 8.2-fold greater than the 2001WT strain.  277 
 278 
In Experiment B, the RCV (Reg_Col) had an IC50 of 0.83 +/- 0.096 µg/ml, 279 
significantly greater than the 2001WT strain (p = 0.0011; Supplementary Figure 4c). 280 
The co-isolated SCV (Small_Col) was not sensitive to caspofungin concentrations up 281 
to 2.4 µg/ml (Supplementary Figure 4d) and had an IC50 of 4.71 +/- 0.236 µg/ml, 5.7-282 
fold greater than the regular co-isolated colony variant and 14.7-fold greater than the 283 
2001WT strain.    284 
 285 
Divergent phenotypic stability of independently-evolved SCVs, in the absence 286 
of drug 287 
We investigated stability of the resistant small colony variants, individually isolated 288 
from the single population from each of Experiment A and B. For this we serially 289 
passaged three replicate populations seeded from an individual culture of each SCV 290 
(from Experiment A and B), over 14 days in the absence of caspofungin. For 291 
Experiment A, the small colony morphology and resistance level showed no 292 
reversion via appearance of regular-sized colonies after 14 days. The ‘stable’ small 293 
colony phenotype from Experiment A maintained a significantly lower relative growth 294 
rate than the 2001WT strain on the 14th day of transfer in the absence of caspofungin 295 
(t(13) = 21.952, p = 1.169e-11) (Figure 2a). However, after passage relative growth 296 
yield did not significantly differ from the wild-type (t(13) = 1.7375, p = 0.1059) (Figure 297 
2b). The level of resistance displayed by the small colony variant was maintained, 298 
with no growth inhibition between 0 – 2.4 µg/ml of caspofungin (Supplementary 299 
Figure 5: Experiment A). The IC50 values for a single colony of each passaged 300 
population of the SCV from Experiment A (experimental setup as shown in 301 
Supplementary Figure 1d) were as follows: 2.40 +/- 0.146 µg/ml (population 1), 2.33 302 
+/- 0.678 µg/ml (population 2) and 2.70 +/- 0.480 µg/ml (population 3)). This indicated 303 
an underlying stable resistance mechanism and a lack of compensatory fitness 304 
improvement.  305 
 306 
In contrast, the resistant small colony phenotype from Experiment B was 307 
homogeneously reversed in all three passaged replicate populations after 14 days. 308 
The ‘unstable’ small colony phenotype from Experiment B had lost its lower relative 309 
growth rate by the 14th transfer day and was not significantly different from 2001WT 310 
(t(13) = 1.2265, p = 0.2418) (Figure 2c). This small colony variant after passage 311 
showed a significant 1.2-fold lower relative growth yield than the wild type (t(13) = 312 
3.5315, p = 0.003685) (Figure 2d).The resistance level of the passaged populations 313 
decreased but sensitivity levels (IC50 values) were not completely restored to wild-314 
type levels: in two populations the IC50 values were higher than 2001WT (0.49 +/- 315 
0.023 µg/ml; p = 0.000336 (Supplementary Fig. 5: Experiment B- population 1) and 316 
0.44 +/- 0.019 µg/ml; p = 0.00463 (population 2)) but were comparable in the third 317 
population (0.34 +/- 0.055 µg/ml; p = 0.797 (population 3)). Despite independent 318 
evolution of the small colony phenotype in separate populations during caspofungin 319 
treatment, the findings indicate that the SCV isolated from Experiment B evolved a 320 
different but transient mechanism of resistance compared with the SCV from 321 
Experiment A.  322 
 323 
We tested whether resistance seen in the small colony phenotype from Experiment A 324 
and B correlated with genetic differences in hotspot regions of the FKS genes, which 325 
are common targets associated with caspofungin resistance [11, 40]. Sequenced 326 
regions were identical in all strains with no nucleotide changes detected. 327 
Furthermore, we identified no nucleotide differences between strains in an additional 328 
set of genetic targets (CDC6, DOT6, MRPL11, SUI2) putatively associated with 329 
development of caspofungin resistance [11]. 330 
 331 
We then tested competitive fitness of the isolated SCV against the RCV from the 332 
evolved population in Experiment A, over 5 different initial frequencies of the SCV in 333 
the presence of caspofungin (0.78 µg/ml). Relative fitness of the SCV was 334 
significantly greater than one for all initial frequencies, apart from the highest starting 335 
SCV frequency (0.95) when there was no significant difference (Supplementary 336 
Figure 6). Relative fitness of the SCV was significantly negative frequency-dependent 337 
(least-squares linear regression: slope = -4.8990, t = -7.554, df = 42, p = 2.37e-09). 338 
These results lead to a longer-term prediction that a low-frequency of an RCV could 339 
co-exist with a high frequency of an SCV, however the underlying mechanisms of this 340 
dynamic were not explored here.  341 
 342 
Independently-evolved drug-resistant SCVs are not attenuated in virulence 343 
We tested virulence of 2001WT, small colony variants (Experiments A and B) and co-344 
isolated regular colony variants in the wax moth model Galleria mellonella. The 345 
‘stable’ small colony variant from Experiment A was virulent in G. mellonella both 346 
before and after passaging without caspofungin (Figure 3a). Mean larval survival 347 
times were 2.61 ± 0.56 days and 1.93 ± 0.49 days respectively, and we found no 348 
significant differences from 2001WT (2.01 ± 0.44 days; log-rank test p-values = 349 
0.3481 (ExA-S); 0.9834 (ExA-P)) or the co-isolated regular colony variant (2.15 ± 350 
0.51 days; p = 0.438 (ExA-S); 0.9483 (ExA-P)). For the ‘unstable’ small colony 351 
variant from Experiment B we found no significant difference in G. mellonella mean 352 
survival times when comparing states before (1.54 ± 0.32 days) and after (1.14 ± 353 
0.18 days) loss of the phenotype (p = 0.2393) (Figure 3b). No significant differences 354 
in mean larval survival time occurred between 2001WT and either ExB-S (p = 355 
0.5338) or ExB-P (p = 0.08), nor between ExB-R (1.25 ± 0.31 days) and either ExB-S 356 
(p = 0.2825) or ExB-P (p = 0.8389). These findings were consistent with two 357 
additional independent replicate survival studies conducted on separate days 358 
(Supplementary Figures 7 and 8). 359 
 360 
Bootstrapping analysis tested for, but found no evidence of, correlations between 361 
larval survival time (measure of virulence) and either relative growth rates or yields in 362 
3 replicate survival studies (Figure 4, Supplementary Figures 9, 10 and 11). 363 
Further G. mellonella infection studies involving larger sample sizes of drug-evolved 364 
clones would be needed to establish evidence for an absence of correlation. 365 
 366 
Discussion 367 
Our work demonstrates that drug-resistance cost in the form of reduced growth rate, 368 
does not necessarily lead to a marked reduction in virulence. This challenges the 369 
current understanding of the resistance-virulence relationship [8]. Using a clinical 370 
isolate of a deadly human pathogen C. glabrata [25, 26] we conducted in vitro 371 
evolutionary studies in the presence of an antifungal drug and repeatedly evolved a 372 
resistant small colony variant (Figure 1 and Supplementary Figure 4). Despite having 373 
a significantly reduced growth rate compared to the susceptible wild-type, the small 374 
colony variants did not suffer a marked alteration in virulence when tested in G. 375 
mellonella, a well-established model host for detecting virulence differences in C. 376 
glabrata strains [23]. The isolated small colony variants represented a subpopulation 377 
of highly resistant individuals, amongst susceptible sub-populations within a drug-378 
treated population – a hallmark of heteroresistance [12]. Increasingly observed 379 
amongst fungal [10, 47] and bacterial [12] pathogens, heteroresistance presents 380 
challenges for detection and antibiotic susceptibility testing [12]. This can lead to 381 
persistent and recurrent infections [48-50] and missed detection of resistant 382 
subpopulations [51]. 383 
 384 
At the first glance, the small colony morphology and lower growth rate of our isolated 385 
small colony variants resembles the well-known C. glabrata petite phenotype [11, 52, 386 
53]. C. glabrata is known to rapidly evolve resistance to caspofungin [11], a front-line 387 
therapeutic for Candida infections, also used in our study. During patient treatment 388 
with caspofungin for recurring bloodstream candidemia, resistant isolates including a 389 
small colony phenotype were recovered [11]. These small colony isolates were found 390 
to be respiratory-deficient having lost mitochondrial function and were termed petite 391 
mutants. The petite phenotype was first observed in the yeast Saccharomyces 392 
cerevisiae [54] and more recently identified in C. glabrata azole-resistant isolates [52, 393 
53]. However, unlike previously identified caspofungin-resistant petite mutants [11] 394 
our small colony variants do not suffer a reduction in virulence (Figure 3) and can 395 
grow on media containing glycerol as a non-fermentative carbon source, indicating 396 
respiratory function (Supplementary Figure 3). This indicates potential presence of a 397 
different resistance mechanism that co-occurs with virulence, not previously 398 
observed for the cidal (cell-killing) echinocandin drug class [11]. In line with our 399 
findings, a prior study that isolated a C. glabrata azole-resistant petite during clinical 400 
infection identified that it had enhanced virulence but reduced in vitro fitness in the 401 
absence of the drug, compared to the sensitive co-isolated type [55]. Thus we argue 402 
that detection of reduced in vitro growth rate of a sub-population clone [11] is not a 403 
reliable indicator of virulence. 404 
 405 
Our study also indicates that small colony resistance in response to the front-line 406 
antifungals can be both reversible and non-reversible (Supplementary Figure 5) when 407 
the drug is removed. So far, studies on the small colony phenotype have shown 408 
reversibility of growth rate and either reversibility or non-reversibility of resistance 409 
[56]. For example, petite C. glabrata mutants result from stable genetic alteration of 410 
mitochondrial DNA and show upregulation of drug efflux transporters when evolved 411 
with azoles [52, 53, 57]. Stability over passaging in the absence of drug, for the first 412 
study to isolate C. glabrata petite mutants during echinocandin treatment, was not 413 
investigated [11]. In contrast, heteroresistance has consistently proven reversible for 414 
both clinical and environmental isolates of Cryptococcus neoformans exposed to 415 
most commonly used antifungals [58]. Other studies have shown that resistance 416 
achieved through induction is reversible, whilst resistance achieved through selection 417 
is non-reversible in a range of Candida species [59]. Here we show that different 418 
resistance mechanisms could be acting in parallel giving rise to either reversibility or 419 
non-reversibility. Recent studies of bacterial heteroresistance describe stable 420 
heteroresistance to be associated with minimal fitness costs, whereas unstable 421 
heteroresistance has been associated with larger fitness costs leading to 422 
compensatory changes that often reverse resistance [60]. In contrast, we find low 423 
growth rates for both our reversible and non-reversible small colony variants. 424 
Moreover, we show that the resistant small colony phenotype can be stable with 425 
passaging in the absence of antibiotics, without compensatory mechanisms that 426 
restore growth rate as was previously described as a necessity for stability [56]. This 427 
highlights the need for future studies to investigate repeatability of heteroresistance 428 
development and stability across multiple parallel populations. This will lead to better 429 
predictability of evolutionary pathways to resistance development in pathogen 430 
populations [61]. 431 
 432 
Classical theory assumes that growth rate positively correlates with pathogen fitness 433 
and virulence [16, 62-64] due to debilitation of the host [65]. Despite some empirical 434 
support of this classical assumption [19, 66], recent meta-analysis across 61 human 435 
pathogens found that growth rate was negatively correlated with virulence [20]. 436 
Moreover, comparisons of C. glabrata clinical strains found that a fast grower was 437 
less virulent than slower growers [23] with fast growth also being constrained by a 438 
low growth yield [24]. Here, we found no evidence of correlation between virulence 439 
and either growth rate or growth yield.  440 
 441 
Our study further highlights the complex nature of the relationship between pathogen 442 
growth rate and virulence. In particular, existing empirical studies [20, 23, 66, 67] 443 
including ours conducted here, compare virulence between pathogenic strains with 444 
undefined genetic differences. As a result, observed virulence variations cannot be 445 
mechanistically linked to differences in growth traits. In general, this could be due to 446 
confounding effects such as differences in host responses to genetically diverse 447 
pathogens [68] or undefined interactions between pathogen strains [69].  448 
 449 
Here we argue that in order to understand the effect of resistance costs on the 450 
evolution of virulence we need to develop an in-depth, mechanistic understanding of 451 
the relationship between growth rate and virulence. 452 
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  698 
Figure legends 699 
 700 
Figure 1. Sub-population colony diversity in growth fitness and drug 701 
susceptibility in Experiment A. Data are shown for the isolated regular-sized 702 
colony variant and small colony variant from the single population in which colony 703 
diversity was identified. Reg_Col (RCV) = regular-sized colony variant; Small_Col 704 
(SCV) = small colony variant); wild-type ancestral strain = 2001WT. In (a) and (b), 705 
growth values are calculated relative to average values of 2001WT, where a value of 706 
1.0 signifies no change relative to ancestor. N = 12 measurements per colony variant 707 
(measurement in four individual wells of a microtiter plate, repeated separately on 708 
three days). Different symbol shapes (separated by horizontal noise on the x-axis) 709 
represent measurements from separate days. Black points and error bars show 710 
overall means and standard errors. Average relative growth rates (+/- SE): Reg_Col: 711 
0.91 +/- 0.07; Small_Col: 0.09 +/- 0.05. Average relative growth yields (+/- SE): 712 
Reg_Col: 0.99 +/- 0.01; Small_Col: 1.13 +/- 0.03.  Dose response plots (c) and (d) 713 
show final OD of drug-treated populations as a percentage of average growth of the 714 
no-drug treated populations. The same dataset for the ancestral strain (2001WT) is 715 
plotted in (c) and (d). N = 9 measurements per colony variant for each drug 716 
concentration (measurement in three individual wells of a microtiter plate, repeated 717 
separately on three days). Different symbol shapes represent measurements from 718 
separate days. Lines represent best fit of the logistic dose response model. Model-719 
predicted IC50 values +/- SE of the estimated value are shown for each dose 720 
response.  721 
 722 
Figure 2. Final relative growth fitness following passaging without caspofungin 723 
of the single isolated small colony variant from Experiment A and Experiment 724 
B. Plots (a) and (b) show data from the small colony variant isolated from Experiment 725 
A; plots (c) and (d) represent the small colony variant isolated from Experiment B. 726 
The wild-type ancestral strain (2001WT) data is as presented in Figures 1a and b (N 727 
= 12) as this strain was not passaged. N = 3 per small colony variant (different shape 728 
symbol per replicate), representing a single endpoint measurement from each of 729 
three passaged populations seeded from a single culture of the small colony variant. 730 
Growth values are calculated relative to the average values of 2001WT, where a 731 
value of 1.0 signifies no change relative to the ancestor. Experiment A: average 732 
relative growth rate of SCV (+/- SE) = 0.05 +/- 0.04; average relative growth yield of 733 
SCV (+/- SE) = 1.09 +/- 0.01. Experiment B: average relative growth rate of SCV (+/- 734 
SE) = 1.06 +/- 0.09; average relative growth yield of SCV (+/- SE) = 0.81 +/- 0.05.  735 
Black points and error bars represent mean and standard error.  736 
 737 
Figure 3. Virulence of C. glabrata wild-type ancestral, small and regular colony 738 
size variants in G. mellonella larvae. Survival of groups of 20 G. mellonella wax 739 
moth larvae injected with 2.5 x 106 CFU/larva per strain over 7 days incubation at 740 
37°C. These data represent one independent replicate of the survival analysis; the 741 
second and third replicates are presented in Supplementary Figures 7 and 8. (a) WT 742 
= 2001WT ancestral strain, ExA-R = Experiment A regular colony variant, ExA-S = 743 
Experiment A small colony variant, ExA-P = Experiment A passaged small colony 744 
variant. (b) ExB-S = Experiment B small colony variant, ExB-R = Experiment B 745 
regular colony variant, ExB-P = Experiment B passaged small colony variant 746 
(revertant). No significant differences in survival in log-rank tests were found across 747 
Experiment A (p ≥ 0.3481) or Experiment B strains (p ≥ 0.08).    748 
 749 
Figure 4. Growth rate, growth yield and virulence correlations.  Growth traits are 750 
plotted for all strains from Experiments A and B, including regular colony variants and 751 
small colony variants before and after passaging. Data is combined from Figures 1a, 752 
b, 2, 3 and Supplementary Figure 4a and b. Plotted points represent mean values +/- 753 
SE. Growth rate and yield are plotted relative to the wild-type ancestral strain 754 
(2001WT). Strains are labelled as - Experiment A strains: ExA-R (regular colony 755 
variant); ExA-S (small colony variant); ExA-P (passaged “stable” small colony). 756 
Experiment B strains: ExB-R (regular colony variant); ExB-S (small colony variant); 757 
ExB-P (passaged “unstable” small colony). Bootstrapping was performed for both 758 
Linear and Deming regressions, in addition to both Pearson and Spearman but we 759 
found no evidence of correlations between virulence and either relative growth rate 760 
(Supplementary Figure 9a) or relative growth yield (Supplementary Figure 9b).  761 
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SUPPLEMENTAL METHODS 
In vitro evolution of C. glabrata populations on a gradient of caspofungin 
concentrations  
The reference C. glabrata strain ATCC 2001 [1] was used as the wild-type ancestor 
of all evolving replicate populations and was denoted as ‘2001WT’. 2001WT was pre-
grown overnight in YPD (Yeast Peptone Dextrose: 2% w/v bacteriological peptone, 
1% w/v yeast extract, 2% w/v glucose) medium, cells were washed in PBS 
(phosphate-buffered saline) and re-suspended in SC medium (10 mg ml-1 glucose, 
0.67% w/v yeast nitrogen base without amino acids and 0.079% w/v synthetic 
complete supplement mixture (Formedium)). Triplicate populations were evolved 
across a gradient of eight caspofungin concentrations (0.05, 0.08, 0.15, 0.26, 0.45, 
0.78, 1.37, 2.40 µg/ml) of clinical relevance [2] and drug-free condition in a 96-well 
microtiter plate (experimental design shown in Supplementary Figure 1). Initial cell 
density per well was approximately 3.25 x 106 cells/ml. The 96-well plate was sealed 
with aerated transparent film and incubated at 30oC over 24 hours with orbital 
shaking at amplitude 4mm. OD (Optical Density) was read at 650 nm wavelength in a 
Tecan M200 microtiter plate reader.  
We used the lme4 package [3] with R version 3.4.3 [4] to conduct a linear mixed 
effects analysis of the fixed effects of day of the evolutionary experiment and 
caspofungin concentration on relative growth of C. glabrata. ‘Population’ was 
included as a nested random effect within ‘Experiment’ as each population was 
repeatedly measured across days of the evolutionary experiment. We obtained p-
values from likelihood ratio tests comparing the full model with alternative models 
with the individually-removed interaction term or individual fixed effects. 
 
Growth profiling of caspofungin-evolved endpoint colonies 
All nine C. glabrata populations (Experiments A-C) that were evolved at 0.78 µg/ml of 
caspofungin were revived from day 14. This was done by streaking out frozen day 14 
populations on 10 mg ml-1 glucose SC agar and CHROMagar plates (BD 
Biosciences, Oxford, UK) (experimental design shown in Supplementary Figure 1). 
We identified two distinct colony size variants hereby named SCV (Small Colony 
Variant) and RCV (Regular Colony Variant) in a single population from each of 
Experiment A and B but not C and only at 0.78 µg/ml, shown in Supplementary 
Figure 3. The 2001WT strain was growth profiled as a reference alongside a single 
SCV and RCV from the two independent populations (one from Experiment A and the 
other from Experiment B).  
Relative growth rate and final growth yield were obtained by dividing through by the 
mean values of the 2001WT strain. We fitted a linear mixed effects model to relative 
growth rate and yield data from Experiment A and Experiment B using the lme4 
package [3] with R version 3.4.3 [4]. We included colony variant type as a fixed factor 
and day of measurement as a random factor. A likelihood ratio test was used to test 
significance of the fixed factor, by comparison of the full model with an intercept-only 
model. We reported significant between-colony variant differences when the 95% 
confidence interval for the difference in mean growth rate or yield did not span zero. 
 
Dose response profiling 
Dose responses were set up in 96-well microtiter plates, using the same methods as 
described in the first season of the in vitro evolution assay (Supplementary Figure 
1a). Initial cell density per well was approximately 3.25 x 106 cells/ml. 
 
Small colony phenotypes  
Serial passaging 
We tested stability of the randomly-selected SCV isolated from the single evolved 
population exhibiting colony diversity from each of Experiments A and B. A single 
overnight culture of each SCV was adjusted to 3.25 x 105 cells/ml and serially 
passaged (1:30 dilution) in triplicate populations in 10 mg ml-1 glucose SC medium 
over 14 days. Populations were serially diluted and plated on SC agar every 2 days 
to test for changes in colony phenotype, a sign of compensatory fitness change in 
resistant mutants [5]. 
 
 
Characterisation of genomic targets 
The HS1 and HS2 regions of the FKS1 and FKS2 genes were amplified by PCR and 
Sanger-sequenced using primers previously described [6, 7]. Amplification of genes 
CDC6, DOT6, MRPL11, SUI2 was performed using primers described for C. glabrata 
[8]. All PCR reactions contained: 25 µl GoTaq, 2 µl of forward primer (20 µM), 2 µl of 
reverse primer (20 µM), 1ul of DNA template and 20 µl of nuclease-free water. The 
PCR programme was run as follows: DNA denaturation- 95ᵒC for 2 minutes; 35 
cycles: denaturation- 94ᵒC for 30 seconds, annealing for 45 seconds with adjusted 
temperature for each gene target, extension- 72ᵒC for 1 minute; final extension- 72ᵒC 
for 5 minutes. Nucleotide and amino acid sequences were aligned using MEGA 
software [9]. FKS1 and FKS2 hotspot 1 and 2 gene targets were sequenced in both 
the forward and reverse directions; other gene targets were sequenced just in the 
forward direction. 
 
Competitive fitness assay between SCV and RCV (Experiment A) 
To test competitive fitness of the stable SCV isolated from Experiment A against its 
co-isolated RCV, the two colony variants were competed across a set of approximate 
starting frequencies of the SCV (0.1, 0.3, 0.5, 0.7 and 0.9). A least-squares linear 
regression of relative fitness against initial SCV frequency was plotted. Coexistence 
between the SCV and RCV was predicted for the SCV frequency when relative 
fitness was equal to one. The significance of the regression slope was calculated in 
Excel [10]. Significance of relative fitness values above or below one were calculated 
by two-tailed one-sample t-tests in R version 3.4.3 [4]. Data are presented in 
Supplementary Figure 6. 
 
SUPPLEMENTAL RESULTS 
Divergent phenotypic stability of independently-evolved SCVs, in the absence 
of drug 
We then tested competitive fitness of the isolated SCV against the RCV from the 
evolved population in Experiment A, over 5 different initial frequencies of the SCV in 
the presence of caspofungin (0.78 µg/ml). Relative fitness of the SCV was 
significantly greater than one for all initial frequencies, apart from the highest starting 
SCV frequency (0.95) when there was no significant difference (Supplementary 
Figure 6). Relative fitness of the SCV was significantly negative frequency-dependent 
(least-squares linear regression: slope = -4.8990, t = -7.554, df = 42, p = 2.37e-09). 
The SCV had a greater fitness than the RCV when present at an initial frequency 
between 0.1 and 0.8 (relative fitness of SCV significantly greater than one). Above an 
initial SCV frequency of 0.85 (where the regression line intersected with SCV relative 
fitness of one), fitness of the SCV and RCV did not significantly differ. 
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Supplementary Figure 1. Experimental design for evolution of caspofungin 
resistance in C. glabrata populations and phenotypic characterisation of 
diverse sub-population variants. (a) C. glabrata populations evolving on a gradient 
of caspofungin concentrations. Eight caspofungin concentrations representing a 
1.75-fold dilution series were prepared, with a decreasing gradient from columns 2 to 
9. Drug-free control wells were in column 10. Column 11 contained media controls. 
Triplicate populations (wells of plate) were evolved at each drug concentration, via 
serial passaging. At each transfer (24 hours), a new 96-well plate was prepared with 
identical layout. Following daily transfers, remaining volumes of all cell populations 
were mixed with glycerol and the plate was frozen at -80oC. In total, 14 serial 
transfers were performed and the whole experiment was repeated three times 
(Experiments A, B, C). (b) Endpoint (day 14) populations were revived from frozen 
cultures that were evolved at the three highest (post-IC50) caspofungin 
concentrations. Populations were streaked on CHROMagar plates to control against 
bacterial contamination and qualitative differences in colony morphology were 
recorded. No colony size variation was detected in Experiment C. (c) A single colony 
of each size variant (RCV and SCV) was randomnly selected, that had been detected 
in a single population from each of Experiments A and B (evolved at 0.78 µg/ml). A 
freezer stock of each re-streaked colony variant was prepared, from which overnight 
cultures were prepared for future phenotypic analyses (growth fitness and 
caspofungin susceptibility assays). Separate overnight cultures of the colony variants 
were prepared for replicate measurements made on separate days. (d) To test for 
stability of the SCV phenotype isolated in each of Experiments A and B, triplicate 
populations were passaged in a 96-well plate, seeded from a single overnight culture 
prepared from the freezer stock of each previously isolated colony variant in (c). 
During the last transfer cycle (day 14), growth rate and yield measurements of all six 
populations were measured in situ via automated OD profiling. Freezer stocks of the 
six populations were prepared and caspofungin susceptibility assays were later 
performed by revival of the populations on agar and preparation of an overnight 
culture from a single randomnly selected colony per population.  
 
 
Supplementary Figure 2. Changes in growth density of populations of C. 
glabrata strain 2001WT evolving on a gradient of caspofungin concentrations. 
9 independent populations in total (3 populations in each of Experiments A, B and C) 
of C. glabrata were serially transferred daily in each of 8 caspofungin concentrations 
for 14 days. Relative growth % is the final optical density (24 h) of a drug-treated 
population, as a percentage of the average optical density of the no-drug treated 
populations. Data points are shown in different colours for days 1, 7 and 14. Different 
symbol shapes represent data from different Experiments (A, B and C). Mean relative 
growth across all 9 data points at each caspofungin concentration is plotted with 
standard error bars. Relative growth of drug-treated C. glabrata populations was 
significantly influenced by day (p = 4.404e-12) and caspofungin concentration (p < 
2.2e-16).  
 
 Supplementary Figure 3. Sub-population diversity in a drug-evolved 
population. Endpoint heterogeneity was shown in Experiment A for a single 
population after 14 days of transfers in 0.78 µg/ml caspofungin. The CHROMagar 
plate shows the revived population by re-streaking from frozen. All colonies 
(pink/purple) are C. glabrata. The two colony size variants (SCV) and (RCV) re-grew 
on Synthetic Complete medium agar when plated, following separate overnight 
culturing of each in liquid Synthetic Complete medium. Each colony variant could 
grow on Yeast Peptone Dextrose (YPD with 2% w/v glucose) and on Yeast Peptone 
Glycerol (YPG: same medium as YPD with 2% w/v glycerol instead of glucose) agar. 
Dextrose (glucose) can be respired and fermented whereas glycerol can only be 
respired. Colonies were streaked on plates in sectors: wild-type ancestor (2001WT); 
small colony (SCV); regular colony (RCV) (left to right sectors). Growth on YPD and 
YPG was also seen for the SCV and RCV variants isolated in Experiment B. 
 
 
 
 Supplementary Figure 4. Sub-population colony diversity in growth fitness and 
drug susceptibility in a single population evolved in 0.78 µg/ml caspofungin in 
Experiment B. Reg_Col (RCV) = regular-sized colony variant; Small_Col (SCV) = 
small colony variant; wild-type ancestral strain = 2001WT. Plots (a) (relative intrinsic 
growth rate) and (b) show growth in liquid medium over 24 hours in the absence of 
caspofungin. Growth values are calculated relative to average values of 2001WT, 
where a value of 1.0 shows no change relative to the ancestor. Black points and error 
bars overlaying each box represent mean and standard error. N = 12 for 2001WT 
(same data as in Figures 1 and 2) and N = 4 (well replicates on a single day) for the 
other two colony variants. Average relative growth rates (+/- SE): Reg_Col: 0.99 +/- 
0.02; Small_Col: 0.23 +/- 0.02. Average relative growth yields (+/- SE): Reg_Col: 
0.81 +/- 0.01; Small_Col: 1.18 +/- 0.01.  Plots (c) and (d) show growth of populations 
on a gradient of caspofungin concentrations measured as final optical density after 
24-hour growth, as a percentage of average growth of the no-drug treated 
populations. N = 9 for the wild-type ancestor (same data as in Figure 1c and d) for 
each drug concentration. N = 3 (well replicates on a single day)) for the regular-sized 
and small colony variants for each drug concentration. Model-predicted (4-parameter 
logistic) IC50 values +/- SE of the estimated value are shown for each dose 
response.  
  
 Supplementary Figure 5. Stability of the independently-isolated small colony 
phenotypes following serial passaging. The single isolated SCV from each of 
Experiments A and B was passaged in triplicate populations in the absence of 
caspofungin for 14 days. All three populations per colony variant showed highly 
similar endpoint (day 14) colony morphologies and population clone caspofungin 
susceptibilities. Data are presented for a single population and are representative of 
the triplicate populations per colony variant. The plate photographs show both SCVs 
starting with small colony morphology on day 1, which was maintained in passaged 
populations in Experiment A but reversion to wild-type colony size occurred across 
populations in Experiment B on day 14. Dose response profiles are presented for an 
endpoint (day 14) population clone from a single passaged replicate population of 
each colony variant. N = 3 (replicate culture wells of a microtiter plate) per drug 
concentration for each clone. N = 9 for each drug concentration of 2001WT, using the 
same data as in Figure 1c and d. The model-predicted IC50 values +/- SE of the 
estimated value are shown for each colony variant dose response.  
 Supplementary Figure 6. Competitive fitness of the SCV and RCV co-isolated 
from a single evolved population in Experiment A. Fitness of SCV (small colony 
variant) relative to the co-isolated RCV over 24-hour competition in the presence of 
caspofungin, calculated as the ratio of SCV/RCV Malthusian parameters [46]. N = 9 
for each initial fraction. The black continuous line is the best-fit least-squares linear 
regression, with the R-squared correlation coefficient shown. The dotted line 
indicates a relative fitness of 1. Asterisks indicate p values of significance from one-
sample two-tailed t-tests. N.S. = non-significant (p > 0.05). (a) T-test results for initial 
fractions: frac 0.15: t(7) = 5.5315, p = 0.0008768; frac 0.49: t(8) = 10.796, p = 
4.777e-06; frac 0.72: t(8) = 8.0344, p = 4.234e-05; frac 0.82: t(8) = 6.9143, p = 
0.0001227; frac 0.95: t(8) = 1.9116, p = 0.09231.  
 
 
 
 
  
 Supplementary Figure 7. Virulence of C. glabrata wild-type ancestral, small and 
regular colony size variants in G. mellonella larvae (second replicate study). 
Survival of groups of 20 G. mellonella wax moth larvae injected with 2.5 x 106 
CFU/larva per strain over 7-day incubation at 37°C. (a) WT = 2001WT ancestral 
strain, ExA-R = Experiment A regular colony variant, ExA-S = Experiment A small 
colony variant, ExA-P = Experiment A passaged small colony variant. The small 
colony variant was virulent in G. mellonella both before and after passaging without 
caspofungin. Mean larval survival times were 2.69 ± 0.51 days (ExA-S) and 3.56 ± 
0.51 days (ExA-P) respectively, and we found no significant differences from 
2001WT (3.70 ± 0.51 days; log-rank test p-values = 0.163 (ExA-S); 0.5871 (ExA-P)) 
or the co-isolated regular colony variant (2.76 ± 0.47 days; log-rank test p-values = 
0.9802 (ExA-S); 0.3228 (ExA-P)). (b) ExB-S = Experiment B small colony variant, 
ExB-R = Experiment B regular colony variant, ExB-P = Experiment B passaged small 
colony variant (revertant). We found no significant difference in G. mellonella mean 
survival times of the “revertant” small colony variant when comparing states before 
(3.63 ± 0.41 days) and after (2.44 ± 0.42 days) loss of the phenotype (log-rank test, p 
= 0.0786). No significant differences in mean larval survival time occurred between 
2001WT and either ExB-S (p = 0.7177) or ExB-P (p = 0.0785), nor between ExB-R 
(3.34 ± 0.59 days) and either ExB-S (p = 0.8439) or ExB-P (p = 0.3078).  
 
 Supplementary Figure 8. Virulence of C. glabrata wild-type ancestral, small and 
regular colony size variants in G. mellonella larvae (third replicate study). 
Survival of groups of 20 G. mellonella wax moth larvae injected with 2.5 x 106 
CFU/larva per strain over 7-day incubation at 37°C. (a) WT = 2001WT ancestral 
strain, ExA-R = Experiment A regular colony variant, ExA-S = Experiment A small 
colony variant, ExA-P = Experiment A passaged small colony variant. The small 
colony variant was virulent in G. mellonella both before and after passaging without 
caspofungin. Mean larval survival times (+/- SE) were 1.23 ± 0.13 days and 1.54 ± 
0.27 days respectively, and we found no significant differences from 2001WT (1.63 ± 
0.33 days; log-rank test p-values = 0.4743 (ExA-S); 0.808 (ExA-P)) or the co-isolated 
regular colony variant (1.49 ± 0.15 days; log-rank test p-values = 0.1755 (ExA-S); 
0.7745 (ExA-P)). (b) ExB-S = Experiment B small colony variant, ExB-R = 
Experiment B regular colony variant, ExB-P = Experiment B passaged small colony 
variant (revertant). We found no significant difference in G. mellonella mean survival 
times of the “revertant” small colony variant when comparing states before (2.48 ± 
0.48 days) and after (1.70 ± 0.30 days) loss of the phenotype (log-rank test, p = 
0.3425). No significant differences in mean larval survival time occurred between 
2001WT and either ExB-S (p = 0.14) or ExB-P (p = 0.4572), nor between ExB-R 
(2.40 ± 0.47 days) and either ExB-S (p = 0.9597) or ExB-P (p = 0.3698). 
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Supplementary Figure 9. Growth rate, growth yield and virulence (first replicate 
study). Analysis of data presented in Figure 4 where growth traits were plotted 
against larval survival time for all strains from Experiments A and B, including regular 
colony variants and small colony variants before and after passaging. Bootstrapping 
was performed for both Linear and Deming regressions, in addition to both Pearson 
and Spearman correlations. None of these detected a correlation between relative 
growth rates and larval survival times (measure of virulence) (a) nor between relative 
growth yield and virulence (b). 
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Supplementary Figure 10. Growth rate, growth yield and virulence (second 
replicate study). (a) Growth traits are plotted for all strains from Experiments A and 
B, including regular colony variants and small colony variants before and after 
passaging. Data is combined from Figures 1a, b, 2 and Supplementary Figure 7. 
Plotted points represent mean values +/- SE. Growth rate and yield are plotted 
relative to the wild-type ancestral strain (2001WT). Strains are labelled as - 
Experiment A strains: ExA-R (regular colony variant); ExA-S (small colony variant); 
ExA-P (passaged “stable” small colony). Experiment B strains: ExB-R (regular colony 
variant); ExB-S (small colony variant); ExB-P (passaged “unstable” small colony). 
Bootstrapping was performed for both linear and Deming regressions, in addition to 
both Pearson and Spearman correlations. None of these detected a correlation 
between relative growth rates and larval survival times (measure of virulence) (b) nor 
between relative growth yield and virulence (c). 
(a) 
 
 
 
(b) 
 
 
 
0 0.5 1 1.5
unitless (relative growth rate)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 0.5 1 1.5
unitless (relative growth rate)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
0 0.5 1 1.5
unitless (relative g ow h rate)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 .5 1 .5
unitless (rela ive growth rat )
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (rela ive growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 0.5 1 1 5
uni le s (relative growth rate
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
T
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
uni l ss (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 0.5 1 1.5
unitle s (relative g ow h rate
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
T
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 .5 1 .5
uni le s (relativ  growth rat
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
T
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative growth yield)
2
2.5
3
3.5
4
4.5
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
WT
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0 0.5 1 1.5
unitless (relative gro th rate)
0.5
1
1.5
2
2.5
3
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
T
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
0.7 0.8 0.9 1 1.1 1.2
unitless (relative gro th yield)
0.5
1
1.5
2
2.5
3
su
rv
iv
al
 ti
m
e 
(lif
es
pa
n i
n d
ay
s)
T
ExA-R
ExA-S
ExA-P
ExB-R
ExB-S
ExB-P
(c) 
 
 
Supplementary Figure 11. Growth rate, growth yield and virulence (third 
replicate study). (a) Growth traits are plotted for all strains from Experiments A and 
B, including regular colony variants and small colony variants before and after 
passaging. Data is combined from Figures 1a, b, 2 and Supplementary Figure 8. 
Plotted points represent mean values +/- SE. Growth rate and yield are plotted 
relative to the wild-type ancestral strain (2001WT). Strains are labelled as - 
Experiment A strains: ExA-R (regular colony variant); ExA-S (small colony variant); 
ExA-P (passaged “stable” small colony). Experiment B strains: ExB-R (regular colony 
variant); ExB-S (small colony variant); ExB-P (passaged “unstable” small colony). 
Bootstrapping was performed for both linear and Deming regressions, in addition to 
both Pearson and Spearman correlations. None of these detected a correlation 
between relative growth rates and larval survival times (measure of virulence) (b) nor 
between relative growth yield and virulence (c). 
